Study Comparing GDC 695 and Diclofenac Sodium Gel, 3% in Subjects With Actinic Keratoses

NCT ID: NCT02952898

Last Updated: 2020-01-07

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE3
• Total Enrollment: 665 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2016-10-27
• Study Completion Date: 2017-09-06

Brief Summary

This research study is being done to compare the safety and effectiveness of GDC 695 (test drug) against the currently marketed reference drug (diclofenac sodium gel, 3%) and to establish that these two drugs work better than placebo in the treatment of actinic keratosis.

Conditions

Actinic Keratosis

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

Test Drug

GDC 695 gel applied topically as directed.

Group Type: EXPERIMENTAL

GDC 695

Intervention Type: DRUG

GDC 695 is a topical gel.

Reference Drug

Diclofenac sodium gel, 3% applied topically as directed.

Group Type: ACTIVE_COMPARATOR

Diclofenac Sodium Gel, 3%

Intervention Type: DRUG

Diclofenac sodium gel, 3% is an FDA-approved drug.

Placebo

Vehicle gel applied topically as directed.

Group Type: PLACEBO_COMPARATOR

Vehicle gel

Intervention Type: DRUG

Vehicle topical gel contains 0.0% of active drug and is color matched to the other two active test drugs.

Interventions

GDC 695

GDC 695 is a topical gel.

Intervention Type: DRUG

Diclofenac Sodium Gel, 3%

Diclofenac sodium gel, 3% is an FDA-approved drug.

Intervention Type: DRUG

Vehicle gel

Vehicle topical gel contains 0.0% of active drug and is color matched to the other two active test drugs.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Has provided written informed consent.
• Immunocompetent male and/or non-pregnant female, 18 years of age or older.
• Willing and able to apply the test article(s) as directed, comply with study instructions, and commit to all follow-up visits for the duration of the study.
• Clinical diagnosis of actinic keratosis.
• In good general health and free of any disease state or physical condition.
• Women, must be post-menopausal, surgically sterile, or use an effective method of birth control with a negative urine pregnancy test (UPT) at the Baseline Visit (Day 1).

Exclusion Criteria

• Women who are pregnant, breastfeeding, or are planning to become pregnant or breastfeed during the study.
• Is currently enrolled in another investigational drug or device study or has used an investigational drug or investigational device within 30 days prior to the Baseline Visit (Day 1).
• Has the need or plans to be exposed to artificial tanning devices or excessive sunlight during the study.
• Is immunosuppressed (e.g., human immunodeficiency virus [ HIV], systemic malignancy, graft host disease, etc.) or is taking medications that suppress the immune system.
• Has experienced an unsuccessful outcome from previous topical diclofenac sodium therapy.
• Has a history of sensitivity to any of the ingredients in the test articles or other excipients in the test or reference drug.
• Has signs or symptoms consistent with the aspirin (ASA) triad.
• Has used topical medications: corticosteroids, alpha hydroxy acids (e.g., glycolic acid, lactic acid, etc. >5%), beta hydroxy acid (salicylic acid >2%), urea >2%, 5-fluorouracil, diclofenac, imiquimod, ingenol mebutate, aminolevulinic acid (ALA) or prescription retinoids (e.g., tazarotene, adapalene, tretinoin), over-the-counter (OTC) products labeled as scrubs of any kind which are used to smooth the skin (as they contain some form of exfoliant such as nut shells, coffee grounds, polymer particles, etc.) within the selected treatment area (face or bald scalp) within one month prior to the Baseline Visit.
• Has had cryodestruction or chemodestruction, curettage, photodynamic therapy (PDT), surgical excision, or other treatments for AK within the selected treatment area (face or bald scalp) within one month prior to the Baseline Visit.
• Has used oral corticosteroid therapy, interferon, cytotoxic drugs, immunomodulators, immunosuppressive therapies, or retinoids within one month prior to the Baseline Visit.
• Has used oral isotretinoin within six months prior to the Baseline Visit.
• Has used chemical peels, including but not limited to alphahydroxy acid, betahydroxy acid, bichloroacetic acid, trichloroacetic acid, and phenol within the selected treatment area (face or bald scalp) within six months prior to the Baseline Visit.
• Has had dermatologic procedures or surgeries such as: laser resurfacing, PUVA (Psoralen + ultraviolet A) therapy, ultraviolet B (UVB) therapy, ALA-PDT, or dermabrasion within the selected treatment area (face or bald scalp) within six months prior to the Baseline Visit.
• Has lesions suspicious for skin cancer (skin cancer not ruled out by biopsy) or untreated skin cancers within the selected treatment area (face or bald scalp).
• Has active gastrointestinal ulceration or bleeding or has a history of gastrointestinal bleeds due to use of aspirin or other NSAIDs.
• Has severe renal or hepatic impairment.
• Has any condition which, in the investigator's opinion, could interfere with the evaluation of the test drugs or that could make it unsafe or preclude the subject's ability to fully participate in this research study.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Balmoral Medical company

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Site 07

Fort Smith, Arkansas, United States

Site 14

San Diego, California, United States

Site 24

San Ramon, California, United States

Site 22

Clearwater, Florida, United States

Site 01

North Miami Beach, Florida, United States

Site 27

Ocala, Florida, United States

Site 12

Tampa, Florida, United States

Site 05

Carmel, Indiana, United States

Site 02

Plainfield, Indiana, United States

Site 25

Saint Joseph, Missouri, United States

Site 21

Albuquerque, New Mexico, United States

Site 03

Warwick, Rhode Island, United States

Site 26

Anderson, South Carolina, United States

Site 04

Greenville, South Carolina, United States

Site 28

Norfolk, Virginia, United States

Site 10

Spokane, Washington, United States

Countries

United States

Provided Documents

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Other Identifiers

GDC-695-001

Identifier Type: -

Identifier Source: org_study_id